Ramón García‐Sánz

27.1k total citations · 1 hit paper
337 papers, 9.6k citations indexed

About

Ramón García‐Sánz is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Ramón García‐Sánz has authored 337 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Hematology, 116 papers in Genetics and 114 papers in Molecular Biology. Recurrent topics in Ramón García‐Sánz's work include Multiple Myeloma Research and Treatments (138 papers), Chronic Lymphocytic Leukemia Research (101 papers) and Lymphoma Diagnosis and Treatment (89 papers). Ramón García‐Sánz is often cited by papers focused on Multiple Myeloma Research and Treatments (138 papers), Chronic Lymphocytic Leukemia Research (101 papers) and Lymphoma Diagnosis and Treatment (89 papers). Ramón García‐Sánz collaborates with scholars based in Spain, United States and Italy. Ramón García‐Sánz's co-authors include Jesús F. San Miguel, Marcos González, Norma C. Gutiérrez, María‐Victoria Mateos, María Eugenia Sarasquete, Jesús María Hernández‐Rivas, Meletios Α. Dimopoulos, Alberto Órfão, Carmen Chillón and Enrique M. Ocio and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Ramón García‐Sánz

321 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

2018 307 citations Ramón García‐Sánz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ramón García‐Sánz Spain	53	5.5k	4.0k	3.7k	3.1k	2.4k	337	9.6k
Pellegrino Musto Italy	52	5.6k 1.0×	4.3k 1.1×	3.5k 1.0×	2.4k 0.8×	1.6k 0.7×	386	9.7k
Andrew R. Belch Canada	49	4.1k 0.8×	3.9k 1.0×	4.4k 1.2×	1.3k 0.4×	1.6k 0.7×	218	8.9k
Jerry A. Katzmann United States	54	5.4k 1.0×	5.1k 1.3×	2.6k 0.7×	2.6k 0.8×	1.4k 0.6×	171	10.6k
Xavier Leleu France	53	6.9k 1.3×	6.4k 1.6×	4.4k 1.2×	3.0k 1.0×	2.1k 0.9×	457	11.4k
Sylvie Castaigné France	46	6.0k 1.1×	5.1k 1.3×	2.1k 0.6×	1.5k 0.5×	1.3k 0.5×	168	9.2k
Jean‐Luc Harousseau France	69	11.0k 2.0×	8.8k 2.2×	7.0k 1.9×	2.6k 0.8×	2.2k 0.9×	319	15.8k
Nigel H. Russell United Kingdom	57	8.9k 1.6×	4.4k 1.1×	3.3k 0.9×	2.5k 0.8×	1.7k 0.7×	355	12.4k
Gunnar Juliusson Sweden	52	3.3k 0.6×	2.9k 0.7×	2.4k 0.6×	4.4k 1.4×	2.8k 1.1×	189	9.0k
Gert J. Ossenkoppele Netherlands	53	8.6k 1.6×	4.4k 1.1×	2.8k 0.8×	2.8k 0.9×	880 0.4×	279	12.3k
Christian Thiede Germany	56	6.7k 1.2×	3.7k 0.9×	2.2k 0.6×	2.7k 0.9×	2.0k 0.8×	268	12.1k

Countries citing papers authored by Ramón García‐Sánz

Since Specialization

Citations

This map shows the geographic impact of Ramón García‐Sánz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ramón García‐Sánz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ramón García‐Sánz more than expected).

Fields of papers citing papers by Ramón García‐Sánz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ramón García‐Sánz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ramón García‐Sánz. The network helps show where Ramón García‐Sánz may publish in the future.

Co-authorship network of co-authors of Ramón García‐Sánz

This figure shows the co-authorship network connecting the top 25 collaborators of Ramón García‐Sánz. A scholar is included among the top collaborators of Ramón García‐Sánz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ramón García‐Sánz. Ramón García‐Sánz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ribera, Josep‐María, Josep‐María Ribera, Mireia Morgades, et al.. (2024). Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results. HemaSphere. 8(4). e67–e67. 10 indexed citations

Villasboas, José C., Stephen D. Smith, Carlos Grande, et al.. (2024). Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).. Journal of Clinical Oncology. 42(16_suppl). 7058–7058. 1 indexed citations

Herrera, Alex F., Pier Luigi Zinzani, Ann S. LaCasce, et al.. (2024). Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis. Blood Advances. 8(11). 2740–2752. 3 indexed citations

Alcoceba, Miguel, Miguel Marcos, Francisco Javier Gil‐Etayo, et al.. (2024). Killer‐cell immunoglobulin‐like receptor polymorphism is associated with COVID‐19 outcome: Results of a pilot observational study. HLA. 104(2). e15640–e15640. 1 indexed citations

Moreno, David F., Cristina Jiménez, Fernando Escalante, et al.. (2024). Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry. HemaSphere. 8(11). e70029–e70029. 2 indexed citations

García‐Sánz, Ramón, Zachary R. Hunter, Stéphanie Poulain, Marzia Varettoni, & Roger G. Owen. (2023). New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia. Expert Review of Hematology. 16(11). 835–847. 8 indexed citations

Piñana, José Luís, Ramón García‐Sánz, Rodrigo Martino, et al.. (2021). Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 6(3). 848–853. 2 indexed citations

Puig, Noemí, et al.. (2021). Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers. 13(6). 1353–1353. 33 indexed citations

Bartlett, Nancy L., Alex F. Herrera, Eva Domingo‐Doménech, et al.. (2020). A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 136(21). 2401–2409. 107 indexed citations

10.

Rojas, Elizabeta A., Luís A. Corchete, Laura San‐Segundo, et al.. (2017). Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. Clinical Cancer Research. 23(21). 6602–6615. 28 indexed citations

11.

García‐Sánz, Ramón, Albert Oriol, María José Moreno, et al.. (2015). Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica. 100(9). 1207–1213. 24 indexed citations

12.

Misiewicz-Krzemińska, Irena, María Eugenia Sarasquete, Carolina Vicente‐Dueñas, et al.. (2015). Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. Clinical Cancer Research. 22(1). 207–217. 25 indexed citations

13.

Paiva, Bruno, Teresa Paíno, Mercedes Garayoa, et al.. (2013). Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 122(22). 3591–3598. 115 indexed citations

14.

Paiva, Bruno, María‐Belén Vídriales, José J. Pérez, et al.. (2011). The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood. 117(13). 3613–3616. 46 indexed citations

15.

López‐Corral, Lucía, Norma C. Gutiérrez, María‐Belén Vídriales, et al.. (2011). The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. Clinical Cancer Research. 17(7). 1692–1700. 103 indexed citations

16.

Morel, Pierre, Alain Duhamel, Paolo G. Gobbi, et al.. (2009). International prognostic scoring system for Waldenström macroglobulinemia. Blood. 113(18). 4163–4170. 228 indexed citations

17.

Sarasquete, María Eugenia, Ramón García‐Sánz, Luis Marı́n, et al.. (2008). Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 112(7). 2709–2712. 164 indexed citations

18.

Martı́n, Alejandro, Ramón García‐Sánz, José‐Ángel Hernández‐Rivas, et al.. (2002). Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti‐tumour effect. British Journal of Haematology. 118(1). 239–242. 52 indexed citations

19.

Lima, Margarida, Lucas Miranda Marques, Carmen Martín, et al.. (2001). Association of CD4 + /CD56 + /CD57 + /CD8 +dim large granular lymphocytic leukemia, splenic B-cell lymphoma with circulating villous lymphocytes, and idiopathic erythrocytosis. Annals of Hematology. 80(11). 685–690. 14 indexed citations

20.

García‐Sánz, Ramón, et al.. (1994). Co-expression of laminin and a 67 kDa laminin-binding protein in teratocarcinoma embryoid bodies. The International Journal of Developmental Biology. 38(1). 121–126. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact